Viatris appoints new Chief Legal Officer

Viatris Inc. reported a leadership change in its top legal role.

Rhea-AI Filing Summary

Viatris Inc. reported a leadership change in its top legal role. Chief Legal Officer Brian Roman will step down from that position effective February 9, 2026 and remain with the company until April 1, 2026 to support the transition.

In connection with his departure, he will be eligible for separation payments equal to his base salary plus target bonus and a pro rata 2026 bonus, consistent with benefits for similar executives, and would sign a customary release of claims. Viatris also announced that Matthew Maletta, who previously served as Executive Vice President, Chief Legal Officer and Secretary of Endo, Inc. from 2015 to 2025, will join as Chief Legal Officer on February 9, 2026.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive change did Viatris (VTRS) disclose in this 8-K?

Viatris disclosed that Chief Legal Officer Brian Roman will leave his role effective February 9, 2026, remaining as an employee until April 1, 2026 for transition. The company simultaneously appointed experienced pharmaceutical attorney Matthew Maletta as its new Chief Legal Officer effective February 9, 2026.

When will Viatris Chief Legal Officer Brian Roman depart the company?

Brian Roman will cease serving as Chief Legal Officer on February 9, 2026 and remain an employee until April 1, 2026. During this period, he will support transitional activities as Viatris hands over the chief legal role to incoming executive Matthew Maletta.

What severance benefits will Brian Roman receive from Viatris (VTRS)?

Brian Roman will be eligible for separation payments equal to his base salary plus target bonus and a pro rata 2026 bonus. Viatris states these benefits are consistent with severance paid to similarly situated executives and are conditioned on his execution of a customary release of claims.

Who is the new Chief Legal Officer at Viatris (VTRS)?

Viatris appointed Matthew Maletta as Chief Legal Officer effective February 9, 2026. He is described as a seasoned pharmaceutical industry legal professional who served from 2015 to 2025 as Executive Vice President, Chief Legal Officer and Secretary of Endo, Inc., bringing significant sector experience.

Does this Viatris leadership change affect other executive roles?

The disclosure focuses specifically on the Chief Legal Officer transition from Brian Roman to Matthew Maletta. No changes to other executive positions are described, and the filing is signed on behalf of Viatris by Chief Financial Officer Theodora Mistras under the Securities Exchange Act requirements.

What is the timing of the legal leadership transition at Viatris (VTRS)?

The transition is structured so responsibility shifts on February 9, 2026, when Brian Roman stops serving as Chief Legal Officer and Matthew Maletta assumes the role. Roman then remains an employee until April 1, 2026 to help ensure an orderly handover of legal responsibilities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 04:30 PM Learn about SEC filing dates

false000179204400017920442026-01-292026-01-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 29, 2026

VIATRIS INC.

(Exact name of registrant as specified in its charter)

Delaware	001-39695	83-4364296
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

1000 Mylan Boulevard, Canonsburg, Pennsylvania, 15317

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (724) 514-1800

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		VTRS		The NASDAQ Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 5.02         Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 3, 2026, Viatris Inc. (the “Company”) announced that Brian Roman, Chief Legal Officer of the Company, would transition from his role with the Company and cease to serve as Chief Legal Officer effective as of February 9, 2026.  Mr. Roman will remain an employee of the Company until April 1, 2026 for transitional purposes.  In connection with his departure from the Company, Mr. Roman will be eligible to receive separation payments equal to the sum of his base salary plus target bonus and a pro rata bonus for 2026, consistent with severance benefits paid to similarly situated executives.  Mr. Roman would also execute a customary release of claims.

On February 3, 2026, the Company also announced that Matthew Maletta will join the Company as Chief Legal Officer on February 9, 2026.  Mr. Maletta is a seasoned legal professional in the pharmaceutical industry, having served from 2015 to 2025 as Executive Vice President, Chief Legal Officer and Secretary of Endo, Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VIATRIS INC.
Date: February 3, 2026	By:	/s/ Theodora Mistras
		Theodora Mistras
		Chief Financial Officer